GP120-depleted HIV-1 vaccine

Drug Profile

GP120-depleted HIV-1 vaccine

Alternative Names: AG-1661; gp120 depleted HZ321 HIV-1; HIV vaccine - Immune Response; IR-8101; REMUNE; Remune Paediatric; RG-83894

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Salk Institute
  • Developer Immune Response BioPharma
  • Class AIDS vaccines; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in HIV-1-infections in Thailand (IM, Injection)
  • 09 Mar 2017 Immune Response BioPharma announces intention to submit BLA to US FDA for HIV-1 infections (In paediatric population) on 31st March, 2017 (Immune Response BioPharma website, March 2017)
  • 13 Feb 2016 Immune Response BioPharma receives complete response letter from the FDA for GP120-depleted HIV-1 vaccine in HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top